The Duration of Oral Anticoagulant Therapy after a Second Episode of Venous Thromboembolism
Sam Schulman(Hamilton General Hospital), Jonas Boberg, Hans Walter, Sune Nordlander(Västerås Municipality), Stanka Viering, Margareta Holmström(Integrated Cardio Metabolic Centre), Barbro Leijd(Saint Göran Hospital), Gerd Lärfars, Olle Linder(Örebro University Hospital), S. Granqvist(Ersta sjukhus), Peter Nicol, Per Lindmarker, Anders Carlsson, Enno Loogna, S.‐G. Eklund(Södertälje Sjukhus), Martin Hjorth(Integrated Cardio Metabolic Centre)
Cited by 611
Related Papers
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
|Journal of Thrombosis and Haemostasis|2005|4.9k
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
|Journal of Thrombosis and Haemostasis|2009|3.8k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Prevention of VTE in Nonsurgical Patients
|CHEST Journal|2012|2.7k
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
|New England Journal of Medicine|2009|2.6k